Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Transcriptomic profiling of trigeminal nucleus caudalis and spinal cord dorsal horn

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. DNMT1 regulates expression of MHC class i in post-mitotic neurons

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Brain Derived Neurotrophic Factor: epigenetic regulation in psychiatric disorders

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Author Correction: Identification of epilepsy-associated neuronal subtypes and gene expression underlying epileptogenesis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Identification of epilepsy-associated neuronal subtypes and gene expression underlying epileptogenesis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. DNA methylation regulates CHRNA7 transcription and can be modulated by valproate

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Henrik H Hansen
  • Katrine Fabricius
  • Pernille Barkholt
  • Jens D Mikkelsen
  • Jacob Jelsing
  • Charles Pyke
  • Lotte Bjerre Knudsen
  • Niels Vrang
Vis graf over relationer

Exendin-4, a glucagon-like peptide-1 (GLP-1) receptor agonist, have been demonstrated to promote neuroprotection in the rat 6-hydroxydopamine (6-OHDA) neurotoxin model of Parkinson's disease (PD), a neurodegenerative disorder characterized by progressive nigrostriatal dopaminergic neuron loss. In this report, we characterized the effect of a long-acting GLP-1 receptor agonist, liraglutide (500µg/kg/day, s.c.) in the context of a partial or advanced (full) 6-OHDA induced nigral lesion in the rat. Rats received a low (3µg, partial lesion) or high (13.5µg, full lesion) 6-OHDA dose stereotaxically injected into the right medial forebrain bundle (n=17-20 rats per experimental group). Six weeks after induction of a partial nigral dopaminergic lesion, vehicle or liraglutide was administered for four weeks. In the full lesion model, vehicle dosing or liraglutide treatment was applied for a total of six weeks starting three weeks pre-lesion, or administered for three weeks starting on the lesion day. Quantitative stereology was applied to assess the total number of midbrain tyrosine hydroxylase (TH) positive dopaminergic neurons. As compared to vehicle controls, liraglutide had no effect on the rotational responsiveness to d-amphetamine or apomorphine, respectively. In correspondence, while numbers of TH-positive nigral neurons were significantly reduced in the lesion side (partial lesion ≈55%; full lesion ≈90%) liraglutide administration had no influence dopaminergic neuronal loss in either PD model setting. In conclusion, liraglutide showed no neuroprotective effects in the context of moderate or substantial midbrain dopaminergic neuronal loss and associated functional motor deficits in the rat 6-OHDA lesion model of PD.

OriginalsprogEngelsk
TidsskriftBrain Research
Vol/bind1646
Sider (fra-til)354-65
Antal sider12
ISSN0006-8993
DOI
StatusUdgivet - 1 sep. 2016

ID: 49674210